You are here

Initiative Updates: Project Data Sphere

2018

June 06, 2018
Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action
Project Data Sphere

Project Data Sphere®, LLC (PDS) is proud to announce the first peer-accepted publication reporting on the multidisciplinary Immune Checkpoint Inhibitor-associated Myocarditis Workshop convened by PDS with support from the Global Oncology Big Data Alliance (GOBDA) and the Parker Institute for Cancer Immunotherapy (PICI). This Checkpoint Inhibitor Safety Working Group included leading clinicians, academic researchers, pharmaceutical companies and regulatory agencies, including the U.S. FDA, China Food and Drug Administrations (CFDA), and the European Medicines Agency (EMA). It represents the power of PDS to bring together all key stakeholders in a safe common harbor on behalf of cancer patients.

This publication in the international cancer medicine journal, The Oncologist, is the 12th peer-accepted manuscript driven by the principle of data-sharing on which PDS was founded. The manuscript, “Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action,” by Dr. Tomas Neilan, et al., identifies a path forward in understanding, diagnosing and treating this rare but serious heart condition arising in some patients whose cancers have been treated with Immune Cancer Therapy.  

June 01, 2018
Global Oncology Big Data Alliance Reception
Project Data Sphere

On June 1, Project Data Sphere®, LLC (PDS) hosted a reception at the commencement of the 2018 ASCO annual meeting in Chicago to celebrate accomplishments of the Global Oncology Big Data Alliance (GOBDA).  PDS founded GOBDA as a novel strategic organization to provide new opportunities for collaboration and cooperation across industry, academia and the global regulatory authorities.   With our founding GOBDA partner, Merck KGaA, Darmstadt, Germany / EMD Serono, this new organization is initially focused on 3 areas critical to improving outcomes for cancer patients:

  • Rare but serious immuno-related adverse events
  • Rare tumor registries
  • Expanded datasets to drive new research investigations
April 02, 2018
Former GSK Senior Vice President Bill Louv Named Project Data Sphere President
Project Data Sphere

Bill Louv has been appointed President of Project Data Sphere®, LLC (PDS). Bill joins PDS after working in roles of increasing responsibility at GSK – Vice President of Information Technology, Chief Information Officer and Senior Vice President of Core Business Services – where he served as a member of GSK’s Corporate Executive Management team from 2007 through 2016.   
 
Bill’s recognized expertise in not only Information Technology, but also mastery of scientific inference as exemplified by his PhD in Statistics from the University of Florida and executive responsibilities for Global Statistics and Clinical Data Management at Marion Merrell Dow, brings a new era of insight and investigation to PDS. This era will see the wealth of cancer clinical trial data that has been aggregated, and that continues to grow, in PDS’ cancer research platform yield further meaningful and novel insights to the community of cancer researchers, physicians and patients.
 
With data now representing more than 121,000 patient lives leading to the publication of 11 (and increasing in number) peer-accepted manuscripts, the PDS web-based library-laboratory stands poised to deliver new discoveries to improve cancer patient outcomes, and I’m thrilled to have Bill on board to enable the research community to identify these new insights.

2017

October 24, 2017
FDA-PDS Symposium-V
Project Data Sphere

On October 24 near US Food and Drug Administration headquarters in Bethesda, MD, we co-hosted our fifth FDA-PDS Symposium on “Growing Dimensions of Big Data in Cancer Research.” These forums offer a unique opportunity for collaboration between often competing research entries in the world of life sciences: industry, academia and the regulatory agencies that govern them.

Propelled by recent collaborative progress such as the New England Journal of Medicine (NEJM) Project Data Sphere-inspired "Sounding Board" article, "Advantages of a Truly Open-Access Data-Sharing Model" and the issuance of a Letter of Support from Dr. Pazdur, his first as Director of the Oncology Center of Excellence, participants will provide updates and data sharing innovations from the FDA’s Oncology Center of Excellence, the Project Data Sphere initiative, and highlight other advances and opportunities in oncology treatment, research and development and regulatory science.

These Symposia also provide opportunities for open dialogue among oncology and data science leaders from academia, government, and industry, combining rich blend of expertise with a common mission of improving cancer patient outcomes. The discussion at Symposium-IV, for instance, advanced our efforts to promote innovative data-sharing in Immuno-Oncology, one of the most promising areas of contemporary oncology clinical trials.

Dr. Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare (left) and Dr. Martin Murphy, CEO of Project Data Sphere, LLC (right)

September 10, 2017
Global Oncology Big Data Alliance
Project Data Sphere

On September 10, 2017, Project Data Sphere®, LLC, entered into a strategic collaboration with Merck KGaA to jointly lead the Global Oncology Big Data Alliance (GOBDA). The signed Memorandum of Understanding described three critical pillars of this emerging alliance:

• Growing the value of the core Project Data Sphere cancer research platform by providing additional data (in terms of more patients and more trials), as well as new types of data.
• Enabling the development and implementation of a Rare Cancer Patient Registry. This Registry will aggregate in a common platform the limited data available on the treatment of rare cancers. This will help to amplify it as a shared resource for future investigation and
analysis.
• Supporting novel investigations into rare but serious adverse events associated with emerging immuno-oncology therapies.